Results 11 to 20 of about 44,973 (223)

Aerosolized plus intravenous colistin vs intravenous colistin alone for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria: A retrospective cohort study

International Journal of Infectious Diseases, 2021
Objective: To compare the effectiveness and safety of aerosolized (AER) plus intravenous (IV) colistin with IV colistin alone in patients with nosocomial pneumonia (NP) due to multidrug-resistant (MDR) Gram-negative bacteria.
Thamer A. Almangour, Alya Alruwaili, Rehab Almutairi, Aljwhara Alrasheed, Abdullah A. Alhifany, Khalid Eljaaly, Hadeel Alkofide, Abdullah M. Alhammad, Leen Ghonem, Aynaa Alsharidi   +9 more
doaj   +1 more source

Association between the use of colistin for short-term treatment of Gram-negative bacterial infections and the emergence of colistin-resistant Enterobacteriaceae in swine from selected swine farms in Thailand.

PLoS ONE, 2020
Long-term use of colistin for preventing Gram-negative bacterial infections in food animals was prohibited in Thailand in 2017, but it is permitted for short-term treatment.
Pariwat Poolperm, Teerawit Tangkoskul, Chakkrapong Seenama, Naruemon Maknakhon, Visanu Thamlikitkul   +4 more
doaj   +1 more source

Risk factors of colistin safety according to administration routes: Intravenous and aerosolized colistin. [PDF]

PLoS ONE, 2018
BACKGROUND:Nephrotoxicity of intravenous (IV) colistin has impeded its clinical use; aerosolized (AS) colistin may be an alternative, but safety data are lacking. Therefore, this study aimed to evaluate the incidence of acute kidney injury (AKI) and risk
Kyoung Lok Min, Eun Sun Son, Jae Song Kim, Soo Hyun Kim, Sun Mi Jung, Min Jung Chang   +5 more
doaj   +1 more source

Adsorption-desorption and degradation of colistin in soils under aerobic conditions

Ecotoxicology and Environmental Safety, 2022
Colistin has broad-spectrum activity against Gram-negative bacteria and has been considered as the last-resort treatment for multiantibiotic-resistant Gram-negative bacteria infections in human.
Lijuan Peng, Chun Peng, Shulin Fu, Yinsheng Qiu   +3 more
doaj   +1 more source

Investigation of Colistin Heteroresistance and Some Factors Affecting Heteroresistance in Carbapenem-Resistant A. baumannii Strains [PDF]

Mediterranean Journal of Infection, Microbes and Antimicrobials, 2017
Introduction: Colistin can be used in patients infected with carbapenem-resistant Acinetobacter baumannii complex (CR-ABC), but recently resistance to colistin and heteroresistance have been reported.
Deniz GAZEL, Müşerref TATMAN OTKUN
doaj   +1 more source

Assessment of the Synergistic Effect of Seven Antimicrobial Combinations on Extensively Drug-Resistant Acinetobacter baumannii Strains

Annals of Clinical Microbiology, 2022
Background: To solve the difficulty in determining the appropriate treatment regimen for patients infected with extensively drug-resistant Acinetobacter baumannii (XDRAB), it is necessary to develop various strategies to increase the therapeutic effect ...
Choon-Mee Kim, Young-Jin Ko, Ji Ae Choi, Seong-Ho Kang, Geon Park, Sook-Jin Jang   +5 more
doaj   +1 more source

Clonal expansion of colistin-resistant Acinetobacter baumannii isolates in Cape Town, South Africa

International Journal of Infectious Diseases, 2020
Objectives: To describe colistin-resistant Acinetobacter baumannii isolates in Cape Town, South Africa. Methods: A. baumannii isolates identified on Vitek 2 Advanced Expert System were collected from Tygerberg Hospital referral laboratory between 2016 ...
Yolandi Snyman, Andrew Christopher Whitelaw, Sandra Reuter, Angela Dramowski, Motlatji Reratilwe Bonnie Maloba, Mae Newton-Foot   +5 more
doaj   +1 more source

Old drug, new findings: colistin resistance and dependence of [PDF]

Precision and Future Medicine, 2017
Colistin is an old drug, and its use has recently resurged because of increasing antibiotic resistance in gram-negative bacteria such as Acinetobacter baumannii.
Kwan Soo Ko, Yujin Choi, Ji-Young Lee
doaj   +1 more source

Synergistic Activity of Pep16, a Promising New Antibacterial Pseudopeptide against Multidrug-Resistant Organisms, in Combination with Colistin against Multidrug-Resistant Escherichia coli, In Vitro and in a Murine Peritonitis Model

Antibiotics, 2023
Colistin is a drug of last resort to treat extreme drug-resistant Enterobacterales, but is limited by dose-dependent toxicity and the emergence of resistance.
Samuel Chosidow, Bruno Fantin, Irène Nicolas, Jean-Baptiste Mascary, Françoise Chau, Valérie Bordeau, Marie-Clemence Verdier, Pierre Rocheteau, Francois Guérin, Vincent Cattoir, Victoire de Lastours   +10 more
doaj   +1 more source

Colistin Dependency among Colistin-Heteroresistant Acinetobacter baumannii Isolates

Microorganisms, 2021
Colistin dependent (CD) isolates are dependent on colistin for optimal growth. Here we aimed to systematically determine the emergence of CD among colistin-heteroresistant carbapenem-resistant Acinetobacter baumannii (CRAB) isolates. We also examined the
Hadas Kon, Amichay Hameir, Elizabeth Temkin, Alona Keren-Paz, David Schwartz, Vered Schechner, Yehuda Carmeli   +6 more
doaj   +1 more source